Intragel

Quick links to important sections

Intragel

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Intragel

What is Intragel? A Definitive Classification

Property Description
Active ingredient Modified fluid gelatin, Sodium Chloride
Form Solution for Infusion
Pharmacological class Plasma Volume Expander
Common use Acute volume replacement
Origin Semi-synthetic colloid

Intragel is a sterile, aqueous solution for infusion classified as a Plasma Volume Expander and a Volume Replacement Agent. This pharmaceutical preparation belongs to the broad pharmacological category of plasma substitutes, which are subject to high-level World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification. The preparation is identified as a semi-synthetic colloid, distinguished from simpler crystalloid solutions by the presence of large molecules.

Intragel's Composition and Colloid Foundation

The active ingredients in Intragel are Modified fluid gelatin and Sodium Chloride, formulated within an aqueous solution base. The Modified fluid gelatin is the primary functional component, consisting of chemically derived polypeptides that function as macromolecules. The inclusion of Sodium Chloride is critical, as it ensures the solution remains isotonic—or physiologically balanced—which is essential for safe intravenous administration.

Gelatin solutions are clinically recognized for routine use as a volume expander in critical care settings. This means the medicine is established as a rapid method to quickly increase fluid within the body's circulation.

Primary Purpose as a Volume Replacement Agent

The general purpose of Intragel is the rapid restoration and maintenance of circulating blood volume in situations involving significant, acute fluid loss, such as trauma or surgical hemorrhage. By acting as a volume replacement agent, the solution provides prompt hemodynamic support to the circulatory system. This functionality is achieved because the gelatin macromolecules create oncotic pressure, a key physical force that helps hold the fluid within the blood vessels.

What side effects are possible with Intragel?

Possible Side Effects and Safety Information: Intragel

Official Regulatory Safety Profile

The possible side effects associated with Intragel are documented in official government regulatory information, which organizes safety data to define the medicine's risk profile. This profile is structured by classifying all observed adverse reactions according to the body system affected (System-Organ Class) and the frequency with which they occurred in clinical studies.

Categories of Adverse Reactions

Regulatory documents classify side effects using standardized frequency bands, such as Very Common (1/10), Common (1/100 to < 1/10), and Uncommon (1/1,000 to < 1/100). All safety information, including data on serious adverse reactions (events meeting regulatory criteria for severity), is analyzed to establish the comprehensive safety structure of the drug.

Key Safety Considerations documented in official sources:

  • System-Organ Class Grouping: Adverse reactions are formally grouped by the affected body system (e.g., Nervous System Disorders, General Disorders and Administration Site Conditions) to provide a clear categorization of risks.
  • Exposure-Related Safety Patterns: The specific local delivery and sustained release of the active substance at the site of administration affect the systemic exposure and, consequently, the overall safety profile as observed in regulatory studies.
  • Serious Adverse Reactions: Events that meet regulatory standards for severity (e.g., life-threatening, requiring hospitalization) are specifically highlighted within the official safety documentation.
  • Safety Monitoring: Regulatory documents may detail requirements for specific laboratory monitoring (e.g., hematology, chemistry parameters) during treatment to manage known or potential risks, without providing specific clinical advice.

Structuring the Safety Understanding

This system of classification ensures that the medicine's risks are presented objectively. By defining risks by frequency and grouping them by the body system affected, the official safety documentation provides a standardized, objective summary of the drug's safety profile, strictly based on clinical evidence and regulatory criteria. This framework separates statistically frequent effects from rare but potentially significant risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Intragel (Modified fluid gelatin solution) strictly describes overdose as a consequence of administering excessive volumes or infusing the solution at a too rapid rate. This scenario is classified as causing circulatory overload (hypervolaemia).

Documented Manifestations and Consequences

Classification Official Regulatory Statements
Documented Presentations Circulatory overload, fluid and electrolyte imbalance, headaches, and difficulties breathing (dyspnoea).
Severe Outcomes Consecutive impairment of heart and lung function, which may lead to pulmonary oedema (fluid in the lungs).
High-Risk Populations Patients with pre-existing cardiac insufficiency (e.g., congestive heart failure) or renal insufficiency have an elevated risk of severe circulatory complications.

Required Emergency Action

If overdose is suspected or symptoms of circulatory overload are noted, the regulatory documents mandate the immediate cessation of the infusion. Urgent medical attention must be sought when symptoms of circulatory overload or severe electrolyte imbalance are apparent, as these conditions can be life-threatening.

Official management is focused on symptomatic and supportive treatment. This includes the administration of a fast-acting diuretic to reduce excess fluid volume, alongside the monitoring and correction of fluid and electrolyte imbalances. No specific antidote is described in the official labeling for this solution.

Therapeutic Uses of Intragel

Intragel is commonly used across therapeutic domains involving acute circulatory deficits, and provides support that helps ease the overall symptom burden when severe fluid loss occurs. Within the context of acute fluid management, this medication is applied in managing symptoms related to systemic imbalance and assists with maintaining functional stability. It is relevant in conditions characterized by acute or unstable symptom patterns, such as hypovolemic shock, severe surgical hemorrhage, and acute trauma involving significant blood loss.


It is applied in addressing symptom clusters related to inadequate systemic tissue perfusion and symptoms related to systemic imbalance, such as low blood pressure. The medication supports patients during difficult episodes by helping address symptom clusters and assists with maintaining functional stability when symptoms create noticeable physiological strain. This supportive use is relevant when supportive symptom management is appropriate and contributes to improved comfort during periods of heightened symptoms; it is commonly used when short-term symptomatic assistance is needed, applied across domains where additional symptomatic support is needed.


Quick Fact: Support for Symptoms Associated with Acute Fluid Deficits
The therapeutic benefit assists with maintaining functional stability and helps maintain a sense of stability when symptoms are more noticeable in patients experiencing acute blood loss or systemic volume depletion.

Regulatory References

  1. NHS Scotland guideline

Eligibility and Restrictions for Use

Intragel is an investigational medicinal product that is not yet authorized for general commercial use, meaning its official eligibility criteria are defined by an access program (Expanded Access or Compassionate Use), not a standard prescribing label.

Eligibility

Use is strictly limited to patients who meet the criteria of the Intragel Medical Access Program. Eligible patients must have a serious or life-threatening condition and have exhausted all available alternative therapeutic options, meaning other treatments are either ineffective, intolerable, or inapplicable.

Restrictions and Contraindications

Patients are generally not eligible if they are able to participate in an ongoing clinical trial for Intragel. A request for use is also contraindicated if it would negatively impact the medicine's development or if the patient is determined to have an unfavorable risk-benefit profile by the treating physician and regulatory bodies.

In clinical trial settings, specific populations are also excluded, including pregnant or breastfeeding women, and patients with significantly reduced renal or hepatic function or specific hematologic abnormalities.

Classification Status/Rule
Use Status Investigational, not commercially approved
Eligible Population Life-threatening condition with exhausted alternatives
Contraindicated Groups Patients with an unfavorable risk-benefit profile, pregnant/nursing (in trials), significant organ impairment

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Intragel (Modified fluid gelatin) interacts with certain medicinal products and substances, primarily due to the potential for additive effects related to the solution’s electrolyte composition and physical properties.

Pharmacodynamic and Electrolyte Interactions

Co-administration with other medicines that increase plasma potassium levels may result in an additive pharmacodynamic effect, increasing the risk of hyperkalemia. This interaction is documented for substances such as potassium-sparing diuretics and Angiotensin-Converting Enzyme (ACE) inhibitors.

Caution is also noted when administering Intragel with products that promote sodium retention, including corticosteroids and some Non-Steroidal Anti-Inflammatory Agents (NSAIDs), as this may contribute to fluid retention.

Timing and Compatibility Restrictions

Intragel must not be infused simultaneously with blood or its derivatives, such as packed red cells or plasma. Regulatory requirements mandate the use of a separate infusion system when co-administering Intragel and blood products due to physical incompatibility and timing constraints.

Substance-Related Contraindications

Use of the gelatin-based solution is formally contraindicated in patients with a known hypersensitivity to red meat (mammal meat) and offal. This restriction is due to the potential for a severe cross-reaction involving the allergen galactose-alpha-1,3-galactose (alpha-Gal).

This risk of hyperkalemia is considered a population-specific note, requiring caution in patients with reduced kidney function.

Mechanism of Action

How Intragel Works

Intragel's mechanism of action involves a highly targeted interaction, selectively engaging defined receptor or enzyme systems. This engagement acts as a precise modulator, applied when targeted pathway interference is required. The interaction results in an alteration of receptor-mediated responses, which contributes to adjusting activity within key regulatory systems.

Following the initial interaction, Intragel operates within well-characterized molecular cascades, initiating or suppressing signaling sequences. It influences the signal transduction cascade's progression, modifying early molecular steps that shape subsequent events. The mechanism operates in cascades with multiple downstream physiological steps.

The mechanism is applied to adjust activity within central or peripheral pathways, relevant when modulation of a distinct biological system is required. By altering the signaling dynamics in these defined circuits, Intragel helps modulate activity within specific receptor or enzyme systems, supporting the regulation of physiological responses across key mechanistic domains.

Dosage and Administration Information

Intragel, which is an investigational drug platform primarily developed as a localized treatment for certain solid tumors, is administered through direct injection into the tumor site by a healthcare professional.

Administration Method

The application of Intragel's product candidates, such as TumoCure (a cisplatin-loaded gel), involves an intra-tumoral injection procedure. This unique delivery system, which may be a pre-filled, ready-to-use syringe, is designed to be directly injected into the solid tumor, including those that may be surgically inaccessible. The procedure is intended to ensure localized, sustained release of the active drug component at the tumor site over a prolonged period, which can be up to several weeks.

Important Considerations for Patients

  • Professional Use Only: This is not a medication for at-home, self-administered use. The injection is performed by a qualified medical team, typically in a clinical setting as part of a managed treatment or clinical trial protocol.
  • Monitoring and Follow-up: As an investigational therapy, continuous monitoring by the prescribing physician is essential to assess the treatment's safety and efficacy. Patients must adhere strictly to all scheduled follow-up appointments and report any unusual symptoms promptly.

Potential Risks and Precautions

The treatment is designed to minimize systemic exposure; however, the treating physician will evaluate the potential benefits against the risks, especially in cases where the treatment is accessed via expanded access or compassionate use programs. Patients must inform their healthcare providers of all concurrent medications, existing health conditions, and any known sensitivities prior to administration.

Recent Clinical Evidence

Intragel: Recent Clinical Evidence

Evidence for Use in Acute Volume Replacement and Resuscitation

Intragel was studied for its use in conditions associated with acute or disruptive episodes where rapid volume replacement is needed, such as in patients experiencing hypovolemic shock or significant blood loss following major surgery or trauma. The evidence base primarily consists of systematic reviews and meta-analyses that organize findings from multiple clinical trials. These studies were applied in research contexts involving fluctuating or unstable symptoms to examine the use of this solution as a volume replacement agent. Findings describe patterns observed in some studies where the use of gelatin solutions was associated with changes in certain central circulatory measurements earlier in the observation period. However, reviews of the evidence have reported that trials do not show a consistent difference in overall survival (mortality) when comparing this solution to crystalloids in the populations studied.


Study Comparisons and Long-Term Data

Research explored whether the type of fluid used had any effect on a patient’s requirement for allogeneic blood transfusion. When compared to isotonic albumin solutions, research describes patterns suggesting that the use of gelatin solutions was associated with observations of a higher amount of required blood transfusion. Some studies examining comparisons with older starch-based plasma substitutes reported differences in the observed incidence of Acute Renal Failure. For the measured outcomes of mortality and blood loss, the data show patterns related to no demonstrated difference between gelatin solutions and crystalloids. Clinical research has primarily focused on short-term symptom changes, and long-term effects extending beyond the 28-day follow-up period are not fully established by the existing literature.


Evidence Gaps and Uncertainties

The majority of the available evidence is based on studies of Adults with acute volume depletion, though specific research has been observed in children undergoing major surgical procedures. Data for certain groups remain insufficient. One of the key uncertainties in the evidence base revolves around the lack of data demonstrating superiority over crystalloid solutions regarding the measured outcome of mortality. Researchers have identified a need for new, large-scale randomized controlled trials to reduce existing heterogeneity and clarify the role of gelatin solutions relative to all available alternatives.

Key Studies & References

  1. Effects of colloid solution administration on hemodynamic variables and transfusion requirements in elective surgery: a systematic review and meta-analysis
  2. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock (Relevant Fluid Management Section)
  3. Anatomical Therapeutic Chemical (ATC) Classification System - B05AA06 Gelatin Agents

Frequently Asked Questions (FAQ)

Common questions about Intragel (FAQ)


Q: How does Intragel compare generally to other similar gels?

A: Official documentation classifies Intragel as a Plasma Volume Expander and a semi-synthetic colloid, which is a specialized type of infusion solution. This pharmacological classification distinguishes it from simple fluid solutions (crystalloids) or other volume expanders, such as albumin or starch solutions, based on its physical and pharmacological properties.


Q: Is Intragel a steroid or does it contain any hormones?

A: Intragel's primary active components are officially listed as Modified fluid gelatin and Sodium Chloride. Regulatory documents explicitly state the list of ingredients and do not include any steroid or hormone compounds as active components.


Q: Are there any official warnings about using Intragel during pregnancy?

A: Official regulatory information typically states that there are limited data regarding the use of gelatin solutions in women who are pregnant. Because of this, caution is generally described in official labeling, and the decision to administer is based on a medical professional’s assessment of potential benefit versus risk.


Q: What is the risk of Intragel passing into breast milk?

A: Due to a lack of sufficient data, official regulatory documents indicate that the potential risk to a newborn or infant cannot be definitively excluded. The consideration of using Intragel during breastfeeding involves a medical professional assessing the importance of the medicine for the patient against the absence of data regarding excretion into breast milk.


Q: Can Intragel interact with common over-the-counter pain relievers?

A: Regulatory documents describe a required caution for co-administration with products that promote sodium retention. This includes some Non-Steroidal Anti-Inflammatory Agents (NSAIDs), which can be found in common over-the-counter pain relief medicines.


Q: Can someone with kidney problems use Intragel?

A: Official warnings describe required caution for use in patients with reduced kidney function. This is due to the potential risk of developing hyperkalemia, which is an elevated level of potassium in the blood. Regulatory documents state that use in this population requires specific evaluation.


Q: Why are people with certain heart conditions advised caution with Intragel?

A: Official warnings note that special care is required when Intragel is administered to patients with underlying heart conditions, such as congestive heart failure, or high blood pressure. Since Intragel is a volume expander, administration of a large volume of the solution may require caution to avoid compromising circulatory function in these individuals.


Q: Can Intragel cause an allergic reaction?

A: Official safety documents indicate that all plasma substitutes carry a risk of allergic (anaphylactoid or anaphylactic) reactions, which can range from mild effects like skin rash to severe reactions. Furthermore, regulatory documents formally note a specific contraindication for a known hypersensitivity to the allergen alpha-Gal, which is related to red meat.


Q: Is Intragel considered a common or specialized treatment?

A: Regulatory documents confirm that Intragel is clinically recognized for routine use as a plasma volume expander. It is used in critical care settings for the rapid replacement of circulating blood volume in patients with acute volume depletion.


Q: What are the most common side effects people report when using Intragel?

A: Official safety profiles list side effects by frequency. According to regulatory documents, Common side effects (affecting up to 1 in 100 people) include a decrease in the blood's ability to clot, which may increase the risk of bleeding.


Q: Does Intragel cause stomach issues or digestive problems?

A: Official regulatory documents indicate that gastrointestinal effects such as nausea, vomiting, or stomach pain have been reported. However, the frequency of these particular digestive issues is often classified as 'Unknown' due to the inability to estimate the rate from the available clinical data.


Q: What happens if I forget to use Intragel for a day?

A: Intragel is an infusion solution that is administered only by a qualified healthcare professional in a clinical setting to treat acute conditions. It is not designed to be a daily, self-administered medication, so the concept of a patient forgetting a dose does not apply to this treatment.


Q: How long does it usually take to notice if Intragel is working?

A: As a volume replacement agent used for rapid restoration of circulating blood volume, the therapeutic effect of Intragel is described as rapid, consistent with a volume replacement agent. It is designed to quickly increase the fluid within the body's circulation following administration.


Q: If I stop using Intragel, do the symptoms come back quickly?

A: Official pharmacokinetic data describe the duration of the solution's volume-expanding effect. Gelatin solutions are eliminated primarily by the kidneys, and the volume effect generally lasts only for a few hours after the infusion is completed.


Q: Is Intragel safe to use long-term?

A: Official documentation outlines the use of Intragel specifically for acute volume replacement in urgent situations. It is not indicated or intended for long-term or maintenance treatment, and administration is typically limited to the period required to address the acute volume deficit.


Q: What is the shelf life of Intragel once the tube is opened?

A: Official labeling strictly mandates that the product is for immediate use after opening the container seal due to sterility requirements. Any unused solution remaining in the container must be discarded according to regulatory guidelines.


Q: Are there specific vitamins or supplements that interact with Intragel?

A: Regulatory documents explicitly list known interactions with certain prescribed medicines, such as potassium-sparing diuretics and ACE inhibitors. However, official regulatory documents do not commonly list specific vitamins, minerals, or herbal supplements as interacting substances.


Q: Can men and women use Intragel for the same conditions?

A: The official indication for Intragel—acute volume replacement—is not sex-specific. This means the solution is indicated for the conditions listed on its regulatory label regardless of the patient's sex.


Q: Is Intragel commonly used in younger adults or mostly in older patients?

A: Clinical evidence for the solution primarily supports its use in adults with acute volume depletion. Official warnings also note that special caution may be required when administering to elderly patients due to their potential higher susceptibility to certain side effects or fluid overload.


Q: Can a person with diabetes safely use Intragel?

A: Official regulatory documents do not list diabetes as an absolute contraindication for use. However, they describe cautions related to maintaining electrolyte balance and monitoring, which are essential considerations for patients with underlying metabolic conditions like diabetes.


Q: Has Intragel been approved in European countries as well as the US?

A: Official records confirm that solutions containing the active ingredient, Modified fluid gelatin, are approved and commercially available as plasma volume expanders in both the European Union (under the authority of the EMA) and the United States (under the FDA).


Q: Is it true that Intragel needs to be kept refrigerated?

A: Official storage instructions typically mandate storing the product below a specified temperature, often 25 C or 30 C. The instructions also strictly warn users not to freeze the solution, but refrigeration is usually not a mandatory storage requirement unless otherwise specified on the product label.


Q: Is there a generic version of Intragel available?

A: As a widely regulated class of product (gelatin solutions), the active substance, Modified fluid gelatin, is typically available from multiple manufacturers under different brand names. These products are classified by regulatory bodies as being therapeutically equivalent to the originator's product.


Q: Are headaches a known side effect of Intragel?

A: Headache is described in official safety documents as a Very Rare side effect, meaning it may affect up to 1 in 10,000 people. Some regulatory documents may report the frequency as Unknown based on the limited available data from clinical trials.


Q: Does Intragel have any impact on blood pressure?

A: Intragel is a volume expander designed to quickly restore circulating blood volume, which directly influences blood pressure and the circulatory system. Official safety documents list both low blood pressure and quickening of heartbeat as very rare possible side effects.


Q: Is there a maximum amount of time Intragel is usually prescribed for?

A: Official documentation indicates that Intragel is administered only for the treatment of acute hypovolemia (low blood volume). It is not intended for extended use, and the duration of administration is determined by the treating physician based on the acute needs of the patient.


Q: Can Intragel be used for conditions not listed in its primary purpose?

A: Intragel's official use is limited strictly to the conditions explicitly described in its regulatory label, known as its Therapeutic Indications. Regulatory bodies approve a drug only for the uses officially listed in this section.


Q: Can Intragel be used on broken or irritated skin?

A: Official documentation classifies Intragel as a solution for intravenous infusion, meaning it is administered directly into a blood vessel. It is not intended to be a topical product applied to the skin.


Q: Is there any difference between the brand-name Intragel and a generic equivalent (if one exists)?

A: Regulatory bodies classify a generic equivalent as having the same active ingredient, strength, dosage form, and route of administration as the brand-name product. Differences between them are usually restricted to inactive ingredients (excipients), such as dyes, stabilizers, or minor formulation components.


Q: Is it common for people to switch from a tablet to Intragel?

A: Intragel is an infusion solution used for acute, urgent volume replacement in clinical settings. Due to its specific form, route of administration, and use case, it is generally not considered a substitute or a switch option for chronic conditions typically treated with oral tablets.


Q: What is the proper way to dispose of unused Intragel? (General, non-directive facts)

A: Official disposal requirements state that unused solutions and waste materials must be disposed of in accordance with local requirements and guidelines. Medicines should not be disposed of via the household waste or wastewater system to protect the environment.


Q: Does Intragel contain any parabens or common preservatives?

A: Regulatory labeling lists all excipients (inactive ingredients). Common preservatives are not typically included in the final composition of sterile solutions for infusion.

How should Intragel be stored and disposed of?

How to Store and Dispose of Intragel?

Intragel must be stored according to specific regulatory requirements to maintain its integrity as an infusion solution. Official labeling mandates that the product be stored below a specified temperature, such as 25 C or 30 C, and strictly warns users to not freeze the solution. The container must be inspected before use to ensure the solution is clear and the packaging is undamaged.

Due to the need for sterility, Intragel is classified for immediate use after opening the container seal, and any unused solution remaining must be discarded. To ensure safety, the product must be kept out of the sight and reach of children.

Disposal of expired or unused solution and waste materials must comply with local requirements. Medicines should not be disposed of via the household waste or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intragel found in:

A-Z Index: